Lee D. Cranmer

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

Robert H.I. Andtbacka, Howard L. Kaufman, Frances A. Collichio et al. · Journal of Clinical Oncology · 2015 · 2.5K citations · Full text

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Antoni Ribas, Igor Puzanov, Reinhard Dummer et al. · The Lancet Oncology · 2015 · 1.5K citations · Full text

Medicine, Melanoma, Immunology +10

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

Evan M. Hersh, Steven O’Day, John D. Powderly et al. · Investigational New Drugs · 2010 · 302 citations

Chemotherapy-naïve Patients, Medicine, Melanoma +7

Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial

Robert H.I. Andtbacka, Merrick Ross, Igor Puzanov et al. · Annals of Surgical Oncology · 2016 · 295 citations · Full text

Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial

William D. Tap, Zsuzsanna Pápai, Brian A. Van Tine et al. · The Lancet Oncology · 2017 · 293 citations · Full text

Medicine, Randomised Phase 3, Metronomic Therapy +7